STAAR Surgical prelim Q4 net sales ~$76.5M, ICL sales +22%; FY2024 outlook $335-340M

STAAR SURGICAL CO

2023-FY EPS reported $0.43 revenue$322,415,000

Preliminary FY2023 net sales ~$322.5M (+13% YoY); Q4 net sales ~$76.5M (+19% YoY).
Global ICL sales up 22% in Q4 (APAC +26%) and 18% for FY2023; ICL unit growth outpaced refractive industry by 26 points in 2023.
FY2024 net sales guidance of $335-340M, implying ~10% ICL growth in both China and U.S.; GAAP operating margin expected at least breakeven.
Cash and investments ~$230M, up ~$28M from Q3; accounts receivable ~$90M.
Full FY2023 results to be reported on or about Feb 21, 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

STAAR SURGICAL CO reported fiscal year ended December 29, 2023 results: revenue Net sales of approximately $322.5 million for fiscal 2023 (preliminary). Guidance initiated.

Period: fiscal year ended December 29, 2023
Revenue: Net sales of approximately $322.5 million for fiscal 2023 (preliminary)
Guidance: initiated
Result: preliminary results

Exact text from the filing

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL) for myopia, astigmatism and presbyopia, today announced preliminary results for the fourth quarter and fiscal year ended December 29, 2023.

View on SEC.gov

Browse all earnings releases →

STAAR SURGICAL CO filing history →

Source: SEC EDGAR

accession 0000950170-24-002738

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.